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Final Results from Arq 197-209: A Global Randomized Placebo-
controlled Phase 2 Clinical Trial of Erlotinib Plus ARQ 197
Versus Erlotinib Plus Placebo in Previously Treated EGFR-
inhibitor Naı¨ve Patients With Advanced Non-small Cell Lung
Cancer (NSCLC)
J. Von Pawel1, W. Akerley2, W. Brugger3, D. Ferrari4, E. Garmey4, D.
Gerber5, S. Orlov6, R. Ramlau7, L. Sequist8, J. Schiller5, 1Asklepios Klinikum
Gauting, Munich, Germany, 2Huntsman Cancer Institute, University of
Utah/Huntsman Cancer Institute-Intermountain Cancer Care Program, Salt
Lake City, UT, 3Schwarzwald-Baar Clinic, Schwenningen, Germany, 4Ar-
Qule, Inc., Woburn, MA, 5University of Texas Southwestern Medical Center,
Dalla, TX, 6St. Petersburg Pavlov State Medical University, St. Petersburg,
Russian Federation, 7Wielkopolskie Centrum Chorob Pluc i Gruzlicy,
Poznan, Poland, 8Massachusetts General Hospital, Boston, MA
Purpose/Objective(s): ARQ197 is an oral, selective, non-ATP competitive
inhibitor of c-MET (MET), a receptor tyrosine kinase (TK) implicated in cancer
cell migration, invasion, and proliferation. Dual EGFR-MET inhibition is a
promising strategy for overcoming MET-mediated resistance to EGFR inhibi-
tors. A prior phase I trial demonstrated the safety of ARQ197 plus erlotinib and
suggested activity in patients (pts) with advanced NSCLC. This global, random-
ized, placebo-controlled, double-blind trial compared erlotinib plus ARQ197
(EA) versus erlotinib plus placebo (EP) in pts with advanced NSCLC,
previously treated with chemotherapy but EGFR TK inhibitor naive.
Materials/Methods: Pts with advanced NSCLC were randomized to receive
EA or EP. Archival tissue was collected for all pts for k-RAS, EGFR,
and MET analyses. The primary endpoint was PFS and secondary endpoints
included safety, ORR, OS, and subgroup analyses.
Results: 167 pts were randomized to EA (84 pts) or EP (83 pts). Mean age
was 63 yrs and baseline characteristics were well balanced for sex, race, country
of origin, and smoking history. Imbalances favoring the placebo arm were
observed for NSCLC histology, EGFR mutations, and k-RAS mutations. Pre-
viously reported PFS and OS were prolonged with EA (medians  16.1 wks
and 36.6 wks) vs. EP (9.7 wks and 29.4 wks) among ITT pts (HRs of 0.81 and
0.88 respectively). A pre-defined multivariable Cox regression model adjusting
for prognostic factors showed EA PFS was significantly superior to EP (HR
0.68; p0.05). PFS improvement was prominent among subgroups with non-
squamous histology, EGFR wild-type status, and k-RAS mutations. Preliminary
safety analysis revealed no major differences between treatment arms.
Conclusions: ARQ-197 combined with erlotinib for 2nd/3rd line treatment of
EGFR-inhibitor naı¨ve NSCLC appears well-tolerated and to prolong PFS and
OS. Particular benefit was observed among pts with non-squamous histology,
k-RAS mutations, and EGFR wild-type status. Final survival, response rate,
safety, and biolologic sub-group data will be presented.
Author Disclosure Block: J. Von Pawel: F. Consulting/Advisory Board;
ArQule NSCLC Advisory Board, January, 2010. W. Akerley: ArQule
NSCLC NSCLC Advisory Board. W. Brugger: None. D. Ferrari: A.
Employment; ArQule, Inc. E. Garmey: ArQule, Inc. D. Gerber: None. S.
Orlov: None. R. Ramlau: None. L. Sequist: F. Consulting/Advisory Board;
ArQule, Inc. J. Schiller: ArQule, Inc.
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Small Cell Lung Cancer Harboring EGFR Mutations: Pheno-
type and Genotype Changes Observed With Acquired EGFR
TKI Resistance in EGFR-Mutant NSCLC
L. V. Sequist1, B. Waltman2, D. Dias-Santagata3, S. Gettinger4, P. Fidias1,
A. T. Shaw1, M. Lanuti1, A. J. Iafrate3, M. Mino-Kenudson3, J. A. En-
gelman1, 1Massachusetts General Hospital Cancer Center, Boston, MA,
2Harvard Medical School, Boston, MA, 3Massachusetts General Hospital
Department of Pathology, Boston, MA, 4Yale University Medical School and
Yale Cancer Center, New Haven, CT
Purpose/Objective(s): In EGFR-mutant NSCLC treated with EGFR ty-
rosine kinase inhibitors (TKIs), drug resistance invariably occurs at 9-12
months due to T790M (50%) and MET amplification (10-15%). Elucidating
the unknown mechanisms of drug resistance in the remaining 35-40% of pts
is of great clinical and scientific significance. We have obtained repeat tumor
tissue biopsies at the time of acquired drug resistance in EGFR-mutant
patients whenever possible over the past two years, and have now accumu-
lated 37 patients with paired pre- and post-resistance samples.
Materials/Methods: Paired tumor samples underwent routine histology
evaluation, including immunohistochemistry staining. All cases were also
genotyped using SNaPshot, a multiplexed PCR-based assay performed in a
CLIA-certified lab using tumor DNA from paraffin-embedded samples.
SNaPshot tests for common mutations in 13 key cancer genes such as EGFR,
KRAS, PIK3CA, BRAF, and TP53. Cases with sufficient tumor tissue
underwent FISH analysis for MET and EGFR gene copy number.
Results: The 37 patients included 15 men and 22 women ranging in age from
37-88 years (median 60). All had clinically responded to either gefitinib or
erlotinib with median length of initial EGFR TKI of 18.4 months (range
4-69). The majority (30, 81%) remained on TKI at the time of repeat biopsy.
Repeat biopsy showed T790M in 18 (49%) and MET amplification in 2
(5%). The histologic diagnosis of the tumor shifted from adenocarcinoma to
SCLC in 5 (14%) cases, all of which retained the initial EGFR mutation with
the transformation to SCLC. Three of the five cases were treated with typical
SCLC-like regimens and responded to therapy. In three other TKI-resistant
patients biopsied on 3 serial occasions each, both genotype and phenotype
were observed to shift from the pre-resistant to the post-resistant state and
back again in response to application and removal of the selective pressure
of an EGFR TKI. This was most pronounced in a case that shifted from
NSCLC to SCLC while on erlotinib, back to NSCLC during a break from
therapy, and after a re-response to erlotinib shifted back to SCLC a second
time upon clinical resistance. Further molecular results will be reported at the
meeting.
Conclusions: Both phenotype and genotype changes can be evoked as
mechanisms for acquired resistance to targeted agents in patients with driver
oncogene mutations. EGFR mutant NSCLC can transform to EGFR mutant
SCLC at the time of EGFR TKI resistance. Our series emphasizes that vast
data can be collected from repeat biopsies and may impact clinical decision
making. Multiple serial biopsies in carefully selected patients should be
considered to broaden our understanding of resistance and facilitate patient
care.
Author Disclosure Block: L.V. Sequist, GSK, F. Consulting/Advisory
Board; Telik, F. Consulting/Advisory Board; B. Waltman, None; D. Dias-
Santagata, Has submitted a patent application for the SNaPshot genotyping
methods, which are the subject of licensing discussions, G. Other; S.
Gettinger, None; P. Fidias, None; A.T. Shaw, None; M. Lanuti, None;
A.J. Iafrate, Has submitted a patent application for the SNaPshot genotyp-
ing methods, which are the subject of licensing discussions, G. Other; M.
Mino-Kenudson, None; J.A. Engelman, None.
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Microscopic Vascular Invasion and its Relationship With T
Size-based Categories in Early Stage Non-small Cell Lung Can-
cer: Did the 2009 TNM Staging System Miss Something?
E. Ruffini1, S. Asioli2, P. L. Filosso1, L. Buffoni3, U. Ricardi4, A. Filippi4,
E. Paze`3, L. Delsedime2, A. Oliaro1, 1University of Torino, Thoracic Sur-
gery, Torino, Italy, 2University of Torino, Pathology, Torino, Italy, 3Medical
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Oncology, S. Giovanni Battista Hospital, Torino, Italy, 4University of Torino,
Radiation Oncology, Torino, Italy
Purpose/Objective(s): The significance of Microscopic Vascular Invasion
(MVI) in patients with non-small cell lung carcinoma (NSCLC) remains
controversial and no TNM edition has so far included MVI as a major
determinant in the staging. Conversely, the 2009 TNM edition of lung tumors
has stressed the importance of tumor size as a major prognostic factor in
NSCLC. To date, the relationship among these two variables remains
unclear. The aim of the present study was to assess the inter-relationship and
the relative prognostic importance of MVI and tumor size in a surgical
population of resected patients with early stage NSCLC.
Materials/Methods: From 1/1998 to 8/2008 1515 patients received resec-
tion for NSCLC at our Institution. Of these, 512 had pathological T
size-based stage T1a-T3N0M0 according to the 2009 TNM staging system.
Patients with T2-T3 non-size-based determinants were excluded from the
study. Histology included 224 adenocarcinomas (ADK) (44%), 227 squa-
mous cell carcinomas (SCC) (44%), 41 bronchioloalveolar carcinomas
(BAC) (8%), 14 large cell anaplastic carcinomas (LCC) (3%), 6 other types.
MVI was ascertained using histopathological and immunohistochemical
(antibody anti-CD34) techniques.
Results: MVI was observed in 154 patients (30%). MVI prevalence was
significantly higher in ADK than in SCC (p0.0001). A significant corre-
lation was found between the presence of MVI and ADK (OR 1.32, 95%CI
1.09-2.74, p0.0003), increased tumor dimension (OR 1.31, 95%CI 1.18-
1.45, p0.009) and the presence of Tumor-infiltrating lymphocytes (TIL)
(OR 1.65, 95%CI 1.03-2.63, p0.03). Patients were stratifyied by T-size
category (T1a,T1b,T2a,T2b,T3) and MVI (MVI, MVI-). Five-year survival
rates in each MVI() size category was lower than the corresponding
MVI(-) size category (T1a 75% vs, 62%, T1b 58% vs. 52%, T2a 66% vs.
52%, T2b 58% vs. 39%, T3 48% vs. 25%, p0.0001). There was no
significant survival rate difference among MVI() T1a-T3 groups (p0.23),
while the difference was significant among MVI(-) T1a-T3 (p0.04). In
multivariate analysis, MVI was a stronger prognostic indicator (HR 1.43,
95%CI 1.04-1.94, p0.02) than tumor size determinant (HR 1.06, 95%CI
0.99-1.13, p0.06) in all T-size categories.
Conclusions: MVI is a powerful prognostic indicator in early stage NSCLC.
It correlates with adenocarcinoma histotype, increased tumor dimensions and
TIL. In all size groups, MVI resulted a stronger prognostic determinant than
the size-based categories proposed by the 2009 TNM staging system, and its
presence resulted in upstaging of the conventional stage. As a final conse-
quence, our study suggests that adjuvant chemotherapy in this high-risk
group of patients may be considered.
Author Disclosure Block: E. Ruffini: None. S. Asioli: None. P.L. Filosso:
None. L. Buffoni: None. U. Ricardi: None. A. Filippi: None. E. Paze`:
None. L. Delsedime: None. A. Oliaro: None.
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Comparison of VATS Lobectomy to Thoracotomy Lobectomy:
Current Indication and Oncologic Outcomes
I. Park, J. Lee, D. Kim, C. Lee, K. Chung, Yonsei University College of
Medicine, Seoul, Korea, Republic of
Purpose/Objective(s): The aims of this study are to validate the current
indication for VATS lobectomy and to evaluate oncologic efficacy of VATS
lobectomy by comparison with thoracotomy lobectomy.
Materials/Methods: Data of surgically treated patients with non-small cell
lung cancer from Jan, 1990 to Nov, 2009 were reviewed retrospectively.
Data were extracted from institutional prospective database for lung cancer
surgery. Inclusion criteria were lobectomy and clinical stage I or II. Exclu-
sion criteria were medical history of cancer and preoperative neoadjuvant
treatment. Eligible patients were divided into VATS group or thoracotomy
group according to intended approach. Feasibility of VATS was evaluated by
comparing morbidity and mortality rates with thoracotomy. Overall and
disease-free survival rates according to clinical and pathologic stage of both
groups were compared to evaluate adequacy of indication and oncologic
outcomes. This study was approved by Institutional Review Board.
Results: Out of the 2190 patients, 739 patients were eligible. Preoperatively,
VATS lobectomy was indicated in 217 patients and conversion to thoracot-
omy was necessary in 15 (6.9%) patients. Excepting 4 patients considered as
unsuitable for VATS before start of lobectomy, VATS lobectomy was tried
in 213 patients. Thoracotomy lobectomy was tried in 526 patients. Demo-
graphic characteristics, pulmonary function and clinical stage were not
significantly different between two groups, statistically. Operation time,
complication rate, major complication rate and mortality rate were not
significantly different. However, hospital stay was shorter in VATS group. In
VATS group, tumor size was significantly smaller (2.6cm vs 3.4cm, p0.00)
and the proportion of pathologic stage Ia was significantly higher (47% vs
29%, p0.00). Recurrences were detected in 13 patients in VATS group and
2 of them were local recurrences. Overall survival of clinical stage Ia (87%
vs 79%, p0.46) and Ib (87.2% vs 54.5%, p0.16) were not significantly
different between groups. Disease-free survival of clinical stage Ia (70% vs
72.3, p0.75) and Ib (64.6% vs 50.1%, p0.24) were not also significantly
different. Overall survival of pathologic stage Ia (90.9% vs 87.8%, p0.57)
and Ib (96.2% vs 61.4%, p0.12) were not significantly different. Disease-
free survival of pathologic stage Ia (74.9% vs 84.7%, p0.21) and Ib (73.7%
vs 55.5%, p0.23) were not significantly different.
Conclusions: VATS lobectomy is technically feasible and safe surgical
treatment for early stage lung cancer. Current indication for VATS lobec-
tomy based on clinical stage is appropriate and VATS lobectomy is as
effective as thoracotomy in terms of oncologic outcomes.
Author Disclosure Block: I. Park: None. J. Lee: None. D. Kim: None. C.
Lee: None. K. Chung: None.
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Results of a Phase II Study of Stereotactic Body Radiation
Therapy for Operable T1N0M0 Non-small Cell Lung Cancer by
Japan Clinical Oncology Group (JCOG0403)
M. Hiraoka1, Y. Nagata2, T. Shibata3, H. Onishi4, M. Kokubo5, K. Kara-
sawa6, Y. Shioyama7, R. Onimaru8, E. Kunieda9, S. Ishikura10, 1Kyoto
University, Kyoto, Japan, 2Hiroshima University, Hiroshima, Japan, 3JCOG
Data Center, National Cancer Center, Tokyo, Japan, 4Yamanashi Univer-
sity, Kofu, Japan, 5Institute of Biomedical Research and Innovation, Kobe,
Japan, 6Tokyo Metropolitan Komagome Hospital, Tokyo, Japan, 7Kyushu
University, Fukuoka, Japan, 8Hokkaido University, Sapporo, Japan, 9Tokai
University, Kanagawa, Japan, 10Kanagawa Prefecture Cancer Center,
Yokohama, Japan
Purpose/Objective(s): Stereotactic body radiation therapy (SBRT) is a
rapidly prevailing treatment modality for early-stage non-small cell lung
cancer (NSCLC). However only a few trials have been undertaken for
inoperable cases, and no trial has been reported for operable cases so far.
JCOG0403 was designed to prospectively evaluate the safety and efficacy of
SBRT in patients with either operable or medically inoperable T1N0M0
NSCLC. We herewith report results of SBRT for operable patients.
Materials/Methods: The eligibility criteria included histologically or cyto-
logically proven NSCLC, T1N0M0, operability assessed by thoracic sur-
geons, PS 0-2,  20 years old, PaO2  60 torr, FEV1.0  700 ml, and
written informed consent. The prescription was 48 Gy at the isocenter in 4
fractions over 4-8 days. 4-10 MV X rays were allowed. Heterogeneity
corrected doses by pencil beam algorithms were used. The GTV included the
primary tumor only, CTV margin was not considered, and ITV margin and
5 mm setup margin were added. As a quality assurance program, credential-
ing of institutions and an individual case review using the Image-guided
Therapy Center (ITC) remote review tool were performed. The primary
endpoint was the three-year overall survival. The secondary endpoints
included overall survival (OS), progression-free survival (PFS), local-pro-
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gression free survival (LPFS), event-free survival (EFS), toxicity, and
patterns of failure. The sample size was determined so that the 95%
confidence interval for the estimated 3-year OS would be  10% around
expected value of 80%.
Results: Between July 2004 and January 2007, 65 patients were registered
from 15 institutions. The patients characteristics were: male 45, female 20;
median age 79 (range 50-91); median tumor size 21 mm (range 10–30 mm);
adenocarcinomas 40, squamous cell carcinomas 21, others 4; and PS 0/1/2,
43/20/2. All patients completed the protocol treatment. As of November
2009, median follow-up of censored cases was 45.4 months. Of the eligible
64 patients, the 3-year OS was 76.0%, and the 3-year PFS, LPFS, and EFS
were 54.5%, 68.5%, 51.4%, respectively. Grade 3 toxicities observed were
chest pain in 1 (1.5%), dyspnea in 2 (3.1%), hypoxia in 1 (1.5%), and
pneumonitis in 2 (3.1%). No grade 4 and 5 toxicity was observed. A total of
25 patients showed progressions of diseases including 11 local progressions.
Conclusions: SBRT for operable stage I NSCLC is highly effective with
mild toxicity. This treatment has a potential to be an alternative to surgery
and should be considered as a treatment option especially in elderly patients.
Author Disclosure Block: M. Hiraoka: A. Employment; Kyoto University.
B. Research Grant; Varian Medical Systems, Mitsubishi Heavy Medal
Industry. F. Consulting/Advisory Board; Mitsubishi Heavy Medal Industry.
Y. Nagata: None. T. Shibata: None. H. Onishi: None. M. Kokubo: None.
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LACE-Bio: Cross-validation and Pooled Analyses of the Puta-
tive Prognostic/Predictive Biomarkers p27, p16 and cyclin E in
IALT, ANITA, JBR10 and CALGB 9633
R. Pirker1, V. Rousseau2, E. Paris2, M. S. Tsao3, S. Aviel-Ronen3, M.
Taron4, R. Kratzke5, E. Brambilla6, L. Seymour7, M. Filipits1, 1Department
of Medicine I, Medical University of Vienna, Vienna, Austria, 2Institute
Gustave-Roussy, Villejuif, France, 3University Health Network, Princess
Margaret Hospital, and the University of Toronto, Toronto, ON, Canada,
4Catalan Institute of Oncology, Badalona, Spain, 5University of Minnesota,
Minneapolis, MN, 6University Joseph Fourier, Grenoble, France, 7Queens
University, Kingston, ON, Canada
Purpose/Objective(s): Platinum-based adjuvant chemotherapy (CT) im-
proves survival in patients with completely resected non-small cell lung
cancer (NSCLC). Predictive markers may improve the selection of patients
for adjuvant CT. P27Kip1 (p27), p16INK4A (p16) and cyclin E (CyE) are
important regulators of cell cycle and potential markers of malignancy and
response to chemotherapy. Previous studies in the IALT trial suggested that
low p27 expression levels assessed by immunohistochemistry were predic-
tive of chemotherapy benefit. The aim of the present study was to cross-
validate the putative prognostic/predictive biomarkers p27, p16 and cyclin E.
Materials/Methods: LACE-BIO cross-validated the IALT p27 results in
669 patients (pts) from ANITA, JBR.10 and CALGB. Pooled analyses of
IALT and JBR10 examined prognostic and predictive values of p16 and CyE
in 1081 pts. High and low expression marker status was determined from
IALT by the medians of intensity x positivity rate scores for p27 and CyE,
and a score  1 for p16. Prognostic/predictive values of each marker for
overall survival (OS) and disease-free survival (DFS) were tested in a Cox
model stratified by trial and adjusted for clinical and pathological factors.
Results: 46% of pts had high p27 expression in their tumors, which was less
common in squamous cell carcinomas (SCC) and T2 tumors. For OS, p27
status was neither prognostic (HR 0.97, 0.77-1.22, p0.80), nor predictive of
adjuvant CT benefit (interaction p0.83, HR 0.83 vs. 0.87 for high and low
p27, respectively). P27 status was also not prognostic or predictive for DFS.
45% of pts had high CyE and 42% had high p16. High CyE was more
common in SCC (p0.0001) while high p16 was more common among
females (p0.0001) and adenocarcinomas (p0.0001). CyE and p16 were
neither prognostic (HR 0.98 and 0.96, respectively) nor predictive for OS
(interaction p0.20 and p0.95, respectively) and for DFS (interaction
p0.21 and p0.79, respectively).
Conclusion: The prognostic and predictive values of p27, p16 or cyclin E in
resected NSCLC were not confirmed. These results demonstrate the impor-
tance of robust validation of potential biomarkers prior to their use in clinical
practice. Supported by French Cancer League and Sanofi Aventis and
Canadian Cancer Society Research Institute.
Author Disclosure Block: R. Pirker, None; V. Rousseau, None; E. Paris,
None; M.S. Tsao, None; S. Aviel-Ronen, None; M. Taron, None; R.
Kratzke, None; E. Brambilla, None; L. Seymour, None;M. Filipits, None.
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Cytologic Evaluation of Stapled Lung Parenchyma Debris to
Determine Adequate Surgical Margins
T. Fabian1,2, J. A. Federico2, A. L. Mouhlas1, P. N. Fiedler2, 1Albany
Medical College, Albany, NY, 2Hospital of St. Raphael, New Haven, CT
Purpose/Objective(s): Pathologic evaluation of lung parenchyma margins is
limited and imprecise and at times results in incorrect interpretation of
surgical margins in NSCLC. We sought to evaluate staple line debris
cytology in patients undergoing sub-lobar resections to determine if this
novel technique is reliable in determining adequate or inadequate surgical
margins.
Materials/Methods: A prospective trial evaluating staple line debris cytol-
ogy in 72 patients undergoing diagnostic sub-lobar resection of the lung was
performed at a single institution between November 2007 and June 2009.
Spent stapler cartridges were mixed in 30cc of NS and served as the
cytologic margin. Cytologic margin and surgical specimen were then eval-
uated separately and blinded to one another. Patients in whom sub-lobar
resection was the planned definitive treatment were excluded from this study.
Results: Of 72 wedge specimens 41(57%) were NSCLC. In the 41 NSCLC
specimens initial cytologic evaluation was positive in 8 (20%), surgical
pathology margin was positive in 6(15%), both were positive in 3 (7%) of the
cases. Subsequent unblinded review of both specimens resulted in changed
interpretation of the surgical specimen from negative margin to positive
margin in 3 (7%) of 41 cases. Analysis of staple debris cytology compared
to histopathology demonstrated specificity (98%), sensitivity (78%), and
overall accuracy (94%) using this technique.
Conclusions: Cytologic evaluation of staple line debris is a highly sensitive
and specific test which alters the surgical margin interpretation in 7% of
cases of NSCLC. This could be considered an adjunct to traditional patho-
logic reporting. With increasing utilization of sublobar resection for NSCLC,
further study of the importance of staple line cytology is warranted.
Author Disclosure Block: T. Fabian: B. Research Grant; Covidien. D.
Speaker’s Bureau/Honoraria; Covidien. J.A. Federico: None. A.L.
Mouhlas: None. P.N. Fiedler: None.
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Bax Expression as a Predictive Marker of Survival Benefit in
Non-small Cell Lung Carcinoma Treated by Adjuvant Cispla-
tin-based Chemotherapy
E. Brambilla1, A. Bourredjem2, S. Lantuejoul1, M. S. Tsao3, J. P. Pignon2, R.
Kratzke4, R. Stahel5, J. Y. Douillard6, L. Seymour7, J. C. Soria8, 1Institut
National de la Sante´ et de la Recherche Medicale U823, Universite´ Joseph
Fourier, Department of Pathology, Grenoble, France, 2Biostatistics and
Epidemiology Unit , Institut Gustave Roussy, Paris, France, 3Princess
Margaret Hospital, University of Toronto, Toronto, ON, Canada, 4Depart-
ment of Medicine, The University of Minnesota, Minneapolis,, MN, 5Depart-
ment of Internal Medicine, University Hospital of Zu¨rich, Zu¨rich, Switzer-
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